Keçilerde Tolfenamik Asitin Artan Dozlarda Uygulanmasının Biyokimyasal Parametrelere Etkisi

Year 2020, , 162 - 165, 31.12.2020

Gül Çetin , Erdinç Türk

https://doi.org/10.47027/duvetfd.824424

Cited By: 2

Abstract

Bu araştırmanın amacı keçilerde tolfenamik asitin tek artan dozlarda uygulanmasını takiben biyokimyasal parametrelere etkisini belirlemektir. Çalışmada 18 adet sağlıklı keçi (2  0.4 yaş ve 38  3 kg vücut ağırlığı) kullanıldı. Keçilere tolfenamik asit 2, 4 ve 8 mg/kg tek doz damar içi (IV) yolla uygulandı. Kan örnekleri tolfenamik asit uygulaması öncesi ve uygulamayı takiben 72. saatte alındı. Kan örneklerinden elde edilen serumlardan albümin, alkalen fosfataz (ALP), alanin aminotransferaz (ALT), aspartat aminotransferaz (AST), gamma glutamiltransferaz (GGT), kolesterol, kreatinin, trigliserid, total protein ve üre düzeyleri otoanalizör cihazında ölçüldü. Keçilere tolfenamik asitin 2, 4 ve 8 mg/kg dozlarda IV uygulaması sonrası grup içi ve gruplar arası değerlendirmede albümin, ALP, ALT, AST, GGT, kolesterol, kreatinin, trigliserid, total protein ve üre değerlerinde herhangi farklılık belirlenmedi (P>0.05). Sonuç olarak keçilerde tolfenamik asitin 2, 4 ve 8 mg/kg tek doz IV uygulamasının biyokimyasal parametrelerde önemli değişikliğe neden olmadığı belirlendi. Ancak keçilerde tolfenamik asitin güvenilirliğinin moleküler ve histopatolojik düzeyde belirlenmesine ihtiyaç vardır.

Keywords

Biyokimyasal parametreler, keçi, tolfenamik asit

References

• 1. Kruszewska H, Zareba T, Tyski S. (2002). Search of antimicrobial activity of selected non-antibiotic drugs. Acta Pol Pharm. 59: 436–439.
• 2. Lees P, McKellar QA, Foot R, Gettinby G. (1998). Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 155(3): 275–288.
• 3. Kim HJ, Cho SD, Kim J, et al. (2013). Apoptotic effect of tolfenamic acid on MDA-MB-231 breast cancer cells and xenograft tumors. J Clin Biochem Nutr. 53: 21–26.
• 4. CVMP (1997). Committee for Veterinary Medicinal Products: Tolfenamic Acid Summary Report. EMEA/MRL/183/97-FINAL. Avaiable: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015620.pdf. Accessed 01 October 2020.
• 5. Landoni MF, Cunningham FM, Lees P. (1996). Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Res Vet Sci. 61(1): 26–32.
• 6. Sidhu PK, Landoni MF, Lees P. (2005). Influence of marbofloxacin on the pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. J Vet Pharmacol Ther. 28(1): 109–119.
• 7. Sidhu PK, Landoni MF, Lees P. (2006). Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. Res Vet Sci. 80(1): 79–90.
• 8. Lascelles BDX, Court MH, Hardie EM, Robertson SA. (2007). Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anaesth Analg. 34(4): 228–250.
• 9. Jaussaud P, Guieu D, Bellon C, et al. (1992). Pharmacokinetics of tolfenamic acid in the horse. Equine Vet J. 24(11): 69–72.
• 10. Reddy P, Reddy S, Jyothi K, Sivajothi, Reddy V. (2014). Total uterine prolapse in a 15 years aged doe. IJVHSR. 2(4): 28–30.
• 11. Dinakaran V, Dumka VK. (2013). Pharmacokinetics of tolfenamic acid following two oral dose levels in buffalo calves. J Vet Pharmacol Ther. 36(3): 306–308.
• 12. Anonymous (2020). Avaiable: https://www.agrovetmarket.com/Files/187c26f8-7427-402b-8ee1-20fba394e5b8.pdf. Accessed 01 October 2020.
• 13. Bennett WM, Henrich WL, Stoff JS. (1996). The renal effects of nonsteroidal anti-inflammatory drugs: Summary and recommen- dations. Am J Kidney Dis. 28(1): 56–62.
• 14. Harirforoosh S, Jamali F. (2009). Renal adverse effects of nonste- roidal anti-inflammatory drugs. Expert Opin Drug Saf. 8(6): 669–681.
• 15. McKellar QA, Lees P, Gettinby G. (1994). Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 253(3): 191–200.
• 16. Eskerod O. (1994). Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol. 75: 44–48.
• 17. Hendel J. (1994). The overall safety of tolfenamic acid. Pharmacol Toxicol. 75: 53–55.
• 18. Skapetas B, Bampidis V. (2016). Goat production in the World: present situation and trends. Livest Res Rural Dev. 28(11): 1–6.
• 19. Clark CR. (2013). Antimicrobial drug use in sheep and goats. In: Antimicrobial Therapy in Veterinary Medicine. Giguere S, Prescott JF, Dowling PM (eds.). 5th ed. Ames, Iowa, Blackwell Publishing.
• 20. Matthews J. (2016). Diseases of the goat. In: Hoboken NJ: John Wiley and Sons Limited. 4th ed. pp. 384–393.
• 21. Tekeli IO, Turk E, Durna Corum D, Corum O, Kirgiz FC, Uney K. (2020). Effect of dose on the intravenous pharmacokinetics of tolfenamic acid in goats. J Vet Pharmacol Ther. 43(5): 435–439.
• 22. Corum O, Corum DD, Er A, Yildiz R, Uney K. (2018). Pharmacokinetics and bioavailability of tolfenamic acid in sheep. J Vet Pharmacol Ther. 41(6): 871–877.
• 23. Corum O, Atik O, Corum DD, Er A, Uney K. (2019). Pharmacokinetics of tolfenamic acid in red-eared slider turtles (Trachemys scripta elegans). Vet Anaesth Analg. 46(5): 699–706.
• 24. Patel SD, Sadariya KA, Gothi AK, et al. (2011). Safety of tolfenamic acid following re- peated intramuscular administration in wistar rats. Pharma Sci Monit Int J Pharmaceutical Sci. 2(2): 79–85.
• 25. Yildiz R, Corum O, Atik O, et al. (2019). Changes in novel gastrointestinal and renal injury markers in the blood plasma of sheep following increasing intravenous doses of tolfenamic acid. Acta Vet Hung. 67(1): 87–97.
• 26. Alkan H, Erdem H. (2018). Reproductive use of nonsteroidal antiinflammatory drugs in cows. Atatürk University J Vet Sci. 13(1): 112–120.
• 27. Suleyman H, Demircan B, Karagoz Y. (2007). Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep. 59(3): 247–258.